Avecho Biotechnology (AVE) Q3 2026 TU earnings summary

Executive summary

• Recruitment and dosing resumed for the final cohort of the pivotal Phase III insomnia trial after the interim review recommended proceeding to the original target of 519 participants.

• ~320 additional participants are expected to be enrolled; recruitment is using existing and additional sites, with completion expected within ~12 months once additional sites are operational.

Financial highlights

• Cash was $5.275m at 30 September 2026, down from $6.610m at 30 June; quarterly operating cash outflow was $1.770m.

• Quarterly cash outlays included $1.174m for R&D, $424k for administration and corporate costs, $173k for staff and $54k for patent portfolio costs.

Outlook and guidance

• Successful Phase III completion would be the final clinical step supporting a TGA registration application for the CBD TPM soft-gel capsule.

• Non-dilutive licensing is the preferred funding route for activating additional trial sites; discussions are progressing, but no transaction, timing or terms are assured.

• Work with Sandoz on activities supporting a future TGA submission has gathered pace; meetings with prospective partners are scheduled at BIO-Europe in November 2026.